Cocrystals of quercetin with improved solubility and oral bioavailability.

Flavonoids have been studied extensively due to the observation that diets rich in these compounds are associated with lower incidences of many diseases. One of the most studied flavonoids, quercetin, is also the most abundant of these compounds in the plant kingdom. Numerous therapeutic bioactivities have been identified in vitro. However, its in vivo efficacy in pure form is limited by poor bioavailability, primarily due to its low solubility and consequent low absorption in the gut. Cocrystallization has gained attention recently as a means for improving the physicochemical characteristics of a compound. Here, we synthesized and evaluated four new cocrystals of quercetin (QUE): quercetin:caffeine (QUECAF), quercetin:caffeine:methanol (QUECAF·MeOH), quercetin:isonicotinamide (QUEINM), and quercetin:theobromine dihydrate (QUETBR · 2H(2)O). Each of these cocrystals exhibited pharmacokinetic properties that are vastly superior to those of quercetin alone. Cocrystallization was able to overcome the water insolubility of quercetin, with all four cocrystals exhibiting some degree of solubility. The QUECAF and QUECAF·MeOH cocrystals increased the solubility of QUE by 14- and 8-fold when compared to QUE dihydrate. We hypothesized that this improved solubility would translate into enhanced systemic absorption of QUE. This hypothesis was supported in our pharmacokinetic study. The cocrystals outperformed QUE dihydrate with increases in bioavailability up to nearly 10-fold.

[1]  P. Hollman,et al.  Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man , 1997, FEBS letters.

[2]  W. Regelson,et al.  Review of the biology of Quercetin and related bioflavonoids. , 1995, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[3]  Ning Shan,et al.  The role of cocrystals in pharmaceutical science. , 2008, Drug discovery today.

[4]  S. Wolffram,et al.  Bioavailability and metabolism of the flavonol quercetin in the pig. , 2000, Free radical biology & medicine.

[5]  Allen H. Pekar,et al.  Hybrid insulin cocrystals for controlled release delivery , 2002, Nature Biotechnology.

[6]  A. Shete,et al.  Crystal engineering to improve physicochemical properties of mefloquine hydrochloride , 2010, Drug development and industrial pharmacy.

[7]  J. Schellens,et al.  Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  Jeanette T. Dunlap,et al.  Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. , 2004, Journal of the American Chemical Society.

[9]  Orn Almarsson,et al.  Performance comparison of a co-crystal of carbamazepine with marketed product. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[10]  M. Zoratti,et al.  Ester-based precursors to increase the bioavailability of quercetin. , 2007, Journal of medicinal chemistry.

[11]  Sekhar Surapaneni,et al.  The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. , 2008, Journal of pharmaceutical sciences.

[12]  I. R. Miksa,et al.  Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  Akira Murakami,et al.  Multitargeted cancer prevention by quercetin. , 2008, Cancer letters.

[14]  G. Rimbach,et al.  Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. , 2008, The Journal of nutrition.

[15]  Sandro Chiodo,et al.  Iron chelation by the powerful antioxidant flavonoid quercetin. , 2006, Journal of agricultural and food chemistry.

[16]  I. Erlund,et al.  Bioavailability of Quercetin From Berries and the Diet , 2006, Nutrition and cancer.

[17]  S. Wolffram,et al.  Oral bioavailability of quercetin from different quercetin glycosides in dogs. , 2010, The British journal of nutrition.

[18]  O. Texier,et al.  Bioavailability of rutin and quercetin in rats , 1997, FEBS letters.

[19]  J. Bernstein,et al.  Graph-set analysis of hydrogen-bond patterns in organic crystals. , 1990, Acta crystallographica. Section B, Structural science.

[20]  C. Auger,et al.  Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats. , 2008, Journal of agricultural and food chemistry.

[21]  G. Sheldrick Phase annealing in SHELX-90: direct methods for larger structures , 1990 .

[22]  M. Hertog Epidemiological evidence on potential health properties of flavonoids , 1996, Proceedings of the Nutrition Society.

[23]  Y. El‐Sayed,et al.  Disposition of the Flavonoid Quercetin in Rats After Single Intravenous and Oral Doses , 2003, Drug development and industrial pharmacy.

[24]  R. Burd,et al.  Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. , 2010, Nutrition reviews.

[25]  M. Veit,et al.  Pharmacokinetics and bioavailability of the flavonol quercetin in humans. , 1999, International journal of clinical pharmacology and therapeutics.

[26]  Aeri Park,et al.  Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.

[27]  Michael J. Zaworotko,et al.  Structure―Stability Relationships in Cocrystal Hydrates: Does the Promiscuity of Water Make Crystalline Hydrates the Nemesis of Crystal Engineering? , 2010 .

[28]  S. Wolffram,et al.  The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. , 2003, The Journal of nutrition.

[29]  Chung S. Yang,et al.  DOSE-DEPENDENT LEVELS OF EPIGALLOCATECHIN-3-GALLATE IN HUMAN COLON CANCER CELLS AND MOUSE PLASMA AND TISSUES , 2006, Drug Metabolism and Disposition.

[30]  J. Pang,et al.  Determination of in vitro permeability of drug candidates through a caco-2 cell monolayer by liquid chromatography/tandem mass spectrometry. , 2000, Journal of mass spectrometry : JMS.

[31]  Allan S. Myerson,et al.  Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals , 2011 .

[32]  M. Morris,et al.  Liquid chromatography-tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[33]  Orn Almarsson,et al.  Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. , 2003, Journal of the American Chemical Society.

[34]  L. Howard,et al.  Solubility and solution thermodynamic properties of quercetin and quercetin dihydrate in subcritical water , 2010 .

[35]  J. Terao,et al.  Quercetin's Solubility Affects Its Accumulation in Rat Plasma after Oral Administration† , 1998 .

[36]  R. Gugler,et al.  Disposition of quercetin in man after single oral and intravenous doses , 1975, European Journal of Clinical Pharmacology.

[37]  Louis J. Farrugia,et al.  WinGX suite for small-molecule single-crystal crystallography , 1999 .

[38]  G. Jacobasch,et al.  Pharmacokinetics and Bioavailability of Quercetin Glycosides in Humans , 2001, Journal of clinical pharmacology.

[39]  Miranda L. Cheney,et al.  Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. , 2011, Journal of pharmaceutical sciences.

[40]  O. Texier,et al.  Comparison of the bioavailability of quercetin and catechin in rats. , 1999, Free radical biology & medicine.

[41]  C. Rémésy,et al.  Respective bioavailability of quercetin aglycone and its glycosides in a rat model. , 2000, BioFactors.

[42]  C. Rice-Evans,et al.  Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. , 2003, The Biochemical journal.

[43]  S. Wolffram,et al.  Bioavailability of quercetin in pigs is influenced by the dietary fat content. , 2004, The Journal of nutrition.

[44]  Amjad Alhalaweh,et al.  Bioavailability of indomethacin‐saccharin cocrystals , 2010, The Journal of pharmacy and pharmacology.

[45]  H. Choo,et al.  In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. , 2009, Bioorganic & medicinal chemistry.

[46]  S. Velaga,et al.  Indomethacin–Saccharin Cocrystal: Design, Synthesis and Preliminary Pharmaceutical Characterization , 2008, Pharmaceutical Research.